PT-141 (Bremelanotide)safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for PT-141 (Bremelanotide) as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. PT-141 (Bremelanotide) is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

PT-141 (bremelanotide/Vyleesi) has one of the more thoroughly characterised safety profiles in the sexual-health peptide class, accumulated through the Palatin clinical-development programme and post-marketing surveillance since 2019 FDA approval. The principal documented adverse events include nausea (~40% at licensed dose — the most common adverse event and the principal reason for treatment discontinuation), flushing (~20%), injection-site reactions (~13%), headache (~11%), and occasional focal skin hyperpigmentation with repeated dosing (~1%; more common in individuals with darker baseline skin). The cardiovascular safety profile is the principal specific concern reflected in the FDA labelling. Vyleesi produces modest but consistent transient blood pressure elevation (typical systolic increase of 6 mmHg, diastolic increase of 3 mmHg peaking approximately 3 hours after administration) and modest heart rate elevation. These effects are related to MC4R activation on cardiovascular sympathetic circuits and are dose-dependent. The clinical significance is modest for most patients but the FDA labelling includes contraindication for uncontrolled hypertension and cautions for cardiovascular risk factors. The focal hyperpigmentation effect reflects residual MC1R activity. In some patients repeated dosing produces localised increases in skin pigmentation (particularly on the face, breasts, and gingiva). This is generally reversible on discontinuation but can be problematic cosmetically. The effect is more prominent in individuals with darker baseline skin — a mechanistically expected consequence of MC1R agonism. Sexual-function-related adverse events — including inappropriate or unwanted sexual arousal — have been documented but at low frequency. The FDA labelling advises careful patient selection to ensure the sexual-function pharmacology is appropriate. Serious adverse events specifically attributable to bremelanotide have been uncommon in the clinical-trial and post-marketing experience. Anti-drug antibodies develop in some patients but have not been associated with clinically significant loss of efficacy or safety issues. The on-demand dosing paradigm — maximum 8 doses per month with at least 24 hours between doses — limits cumulative exposure and mitigates the chronic-dosing safety concerns that would apply to daily use. Chronic daily-use safety pharmacology is not characterised because it is not the licensed indication.

UK regulatory status

PT-141 (bremelanotide/Vyleesi) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no UK marketing authorisation. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women in the United States; the EMA has not authorised it in Europe. UK authorisation has not been sought. It is not a controlled substance under the Misuse of Drugs Act 1971. Research-grade material for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration of PT-141 to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — the FDA approval does NOT authorise UK supply or use. Specialist UK access through the unlicensed-medicines 'specials' route (Regulation 167) is theoretically possible for individual patients with HSDD, typically through importation of Vyleesi from US pharmacies. In practice this route is rarely pursued given the availability of alternative approaches for female sexual dysfunction and the specific FDA-labelled patient population. PT-141 is not currently on the WADA Prohibited List. Its sexual-function mechanism does not fall within any current WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, PT-141 work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. PT-141 (Bremelanotide) is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full PT-141 (Bremelanotide) research context including mechanism, study citations, and references, see the main PT-141 (Bremelanotide) research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.